Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal

LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop Biotech will collaborate with Aligos Therapeutics.